Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Almirall ( (ES:ALM) ) has shared an announcement.
Almirall has announced the divestment of its product Algidol® and the licensing of Sekisan® in Spain, receiving €12 million upfront and additional future payments. This move is part of Almirall’s strategy for portfolio rotation and management, potentially streamlining its focus and enhancing financial flexibility.
More about Almirall
Almirall is a pharmaceutical company focusing on the development and marketing of medical products. The company specializes in dermatology and other therapeutic areas, providing treatments for a variety of health conditions.
YTD Price Performance: 17.08%
Average Trading Volume: 3,882
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €2.03B
See more insights into ALM stock on TipRanks’ Stock Analysis page.
